Innovating Works

EFS

Desconocido
ORTHO-ALLO-UNION: ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and non union... ETABLISSEMENT FRANCAIS DU SANG participó en un HORIZON EUROPE HORIZON-HLTH-2023-TOOL-05 Bone fracture with delay or failure to heal is a condition with huge health impact. Although only a small proportion of long bone fractures...
2023-11-28 - 2028-11-30 | Financiado
SUPPORT-E: SUPporting high quality evaluation of COVID 19 convalescent Plasma thrOughoutT Europe ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 Coronavirus disease 19 (COVID-19) is provoking the greatest global health crisis of this generation. With no vaccine or specific antiviral t...
2020-09-02 - 2025-12-31 | Financiado
EVIDENCE: Erythrocytes properties and viability in dependence of flow and extra cellular environment ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 H2020-MSCA-ITN-2019 After exiting the bone marrow, reticulocytes mature to form red blood cells (RBCs) which are highly adapted cells Red blood cells (RBCs) tra...
2019-08-19 - 2023-12-31 | Financiado
MEFISTO: MEFISTO Meniscal functionalised scaffold to prevent knee Osteoarthritis onset after meniscectomy ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 H2020-NMBP-TR-IND-2018-2020 MEFISTO will develop two novel solutions to treat meniscus loss as a strategy for preventing the onset of an epidemic of post-meniscectomy k...
2019-03-05 - 2024-11-30 | Financiado
MAXIBONE: Personalised maxillofacial bone regeneration ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 H2020-SC1-2016-2017 Several tens of millions of European citizens are partially edentulous and have insufficient bone for placement of dental implants. Followin...
2017-11-27 - 2022-06-30 | Financiado
ORTHOUNION: ORTHOpedic randomized clinical trial with expanded bone marrow MSC and bioceramics versus autograft... ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 H2020-SC1-2016-2017 Current orthopaedic treatments permit spontaneous bone regeneration to unite and heal 90% bone injuries. Non-union associates pain and disab...
2016-12-12 - 2022-06-30 | Financiado
RESSTORE: REgenerative Stem cell therapy for STroke in Europe ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 H2020-PHC-2014-2015 Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and co...
2015-09-15 - 2020-08-31 | Financiado
BIOCAPAN: BIOactive implantable CApsule for PANcreatic islets immunosuppression free therapy ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 H2020-NMP-2014-2015 The key therapeutic issue in diabetes mellitus type I and II is glycaemic control. Reductions of constant self-control, of insulin injection...
2015-05-29 - 2019-09-30 | Financiado
Ebola_Tx: Emergency evaluation of convalescent blood and plasma for Ebola Viral Disease EVD in affected West... ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 DIGITAL-2024-CLOUD-AI-06 The objective of this proposal is to urgently determine the efficacy, safety and feasibility of convalescent whole blood (CWB) and convalesc...
2014-12-03 - 2016-10-31 | Financiado
ADIPOA2: Clinical trial of autologous adipose derived mesenchymal stromal cells ASC in the treatment of mil... ETABLISSEMENT FRANCAIS DU SANG participó en un H2020 H2020-PHC-2014-2015 Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to preve...
2014-12-01 - 2019-12-31 | Financiado
CASCADE: Cultivated Adult Stem Cells as Alternative for Damaged tissue ETABLISSEMENT FRANCAIS DU SANG tramitó un FP7 Rapid progress in stem cell research pave the way for the development and use of new cell therapy products in regenerative medicine. The obj...
Financiado
ADIPOA: ADIPOSE DERIVED STROMAL CELLS FOR OSTEOARTHRITIS ETABLISSEMENT FRANCAIS DU SANG participó en un FP7 Osteoarthritis (OA) is a degenerative joint disease for which no efficient therapy is available. The ADIPOA consortium has previously shown...
Financiado
REBORNE: Regenerating Bone defects using New biomedical Engineering approaches ETABLISSEMENT FRANCAIS DU SANG participó en un FP7 Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone repla...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.